Millennium Biltmore Hotel
Los Angeles

Downtown Los Angeles, California


SYMPOSIUM INFORMATION

>General Information
>Faculty
>Program/Schedule
>Accreditation/CME Surveys
>Registration
>Hotel Reservations

 

Supported by:
GOOD SAMARITAN HOSPITAL
Los Angeles, CA


Related Conferences:


24th Annual

Heart Failure 2020
Update on Diagnosis and Therapy
March 14, 2020

2019 CME SURVEYS, SPEAKER SLIDE DOWNLOAD & SYLLABUS
For access to CME surveys and symposium materials, use your registration email address to login. Surveys were due by May 6, 2019. Certificates are available online until January 1, 2020


IMPORTANT CME CREDIT NOTICE
CME Certificates will be issued digitally after Speaker and Symposium Surveys are completed online. Surveys are accessible after signing in with the email address you submitted during registration. Surveys will be accessible online the day of the symposium and for 3 weeks following.

ACCREDITATION
This Live activity, 24th Annual Heart Failure 2020: An Update on Therapy , with a beginning date of 03/14/2020 is currently being reviewed by an accrediting organization to determine credit hour awards.


COURSE OVERVIEW
This year’s program provides a comprehensive update on the prevention, diagnosis and management of heart failure (HF). The program includes lectures presented by experts combined with interactive discussion with faculty. The extensive list of topics has been selected to provide a high level, contemporary and clinically relevant update with a goal of improving the care of patients with heart failure.

PROGRAM OBJECTIVES
At the conclusion of this activity, the participants should be able to:

  1. Implement effective therapy for lipid disorders
  2. Manage diabetes in patients with HF
  3. Use new FDA approved drugs for the treatment of chronic HF
  4. Identify new therapeutic approaches for patients with chronic HF including iron replacement
  5. Review effective management of the hospitalized patients with HF
  6. Review the clinical implications and management strategies of worsening kidney function during treatment of HF
  7. Assess and follow patients with HF using devices for remote hemodynamic monitoring
  8. Manage patients with pulmonary hypertension
  9. Review new information on atrial fibrillation ablation in patients with HF
  10. Provide an update on new biomarkers for the diagnosis and management of patients with HF
  11. Review mechanisms, diagnosis and management of postural tachycardia syndrome
  12. Select appropriate patients with severe HF due to ischemic cardiomyopathy for percutaneous and surgical revascularization
  13. Review results of recent trials and define indications for percutaneous mitral valve repair in patients with HF
  14. Review the mechanisms and hemodynamic effects of bed side circulatory assist devices for the management of severe HF and cardiogenic stroke
  15. Prove an update on new permanent left ventricular assist devices as a bridge to transplantation or as destination therapy
  16. Provide an update on the management of peripartum cardiomyopathy
  17. Provide guidelines for the use of palliative care for HF patients

TARGET AUDIENCE
This program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.

FACULTY DISCLOSURE
It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.